Chief Executive Dale Fisher has announced that she will be leaving Peter MacCallum Cancer Centre to take on a national leadership role as CEO of Silver Chain, a leading home health and aged care provider.
An international clinical trial - led by Peter Mac’s Professor Michael MacManus - has shown that a combination therapy significantly improves long-term disease control for patients with localised, follicular lymphoma compared to radiotherapy alone. Follicular lymphoma is the most common type of low-grade lymphoma and it is a slow progressing disease, making clinical trials difficult to conduct.
A Peter Mac clinical trial using a highly advanced, single-dose radiotherapy treatment has halted the spread of prostate cancer in some men, delaying the need for conventional lifelong hormone therapy.
A compilation of scans of eight Peter Mac patients, created by Professor Michael Hofman and his research team, has been declared “Image of the Year” by the Society of Nuclear Medicine and Molecular Imaging.
Post-doctoral researcher Jess Beach, who specialises in ovarian cancer, moved across the globe to work with Peter Mac’s Professor David Bowtell. She has just started her first clinical trial in ovarian cancer: Targeting the C1 Subtype of High Grade Serous Ovarian Cancer (BEACON).
The Peter MacCallum Cancer Centre acknowledges the traditional
owners of the land on which our five sites are located throughout Victoria.
We recognise their strength and resilience and pay our respects
to their Elders past and present.